|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-6-26
|
|
pubmed:abstractText |
Most patients with non-small cell lung cancer (NSCLC) cannot tolerate a cisplatin-based chemotherapy because of old age, general conditions, and/or multiorgan metastatic sites. Oxaliplatin is active in NSCLC, offers advantage in terms of toxicity, and shows synergism with gemcitabine. The aims of this phase II study were to evaluate the response rate and toxicity of the gemcitabine-oxaliplatin combination in patients with advanced NSCLC and poor prognosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
101-6
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12826318-Adult,
pubmed-meshheading:12826318-Aged,
pubmed-meshheading:12826318-Antimetabolites, Antineoplastic,
pubmed-meshheading:12826318-Antineoplastic Agents,
pubmed-meshheading:12826318-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12826318-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12826318-Deoxycytidine,
pubmed-meshheading:12826318-Female,
pubmed-meshheading:12826318-Humans,
pubmed-meshheading:12826318-Lung Neoplasms,
pubmed-meshheading:12826318-Male,
pubmed-meshheading:12826318-Middle Aged,
pubmed-meshheading:12826318-Organoplatinum Compounds,
pubmed-meshheading:12826318-Prognosis,
pubmed-meshheading:12826318-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
|
|
pubmed:affiliation |
Medical Oncology Unit, University-Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy. vittorio.franciosi@tin.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
